Healthcare investment company
Appears in 1 story
Largest Beacon shareholder at 38.4%
X-linked retinitis pigmentosa gradually destroys the retinas of young men, and no treatment has ever slowed it. Beacon Therapeutics' gene therapy laru-zova is now the first to clear a pivotal trial, and the company says it will file for US approval later this year.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
